These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Sánchez-Danés A, Larsimont JC, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, Del Marmol V, Tabernero J, Blanpain C. Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799 [Abstract] [Full Text] [Related]
3. Hedgehog Pathway Inhibition. Sekulic A, Von Hoff D. Cell; 2016 Feb 25; 164(5):831. PubMed ID: 26919418 [Abstract] [Full Text] [Related]
4. Discovery and preclinical development of vismodegib. Gould SE, Low JA, Marsters JC, Robarge K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H, Yauch RL. Expert Opin Drug Discov; 2014 Aug 25; 9(8):969-84. PubMed ID: 24857041 [Abstract] [Full Text] [Related]
5. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin. Makinodan E, Marneros AG. Exp Dermatol; 2012 Nov 25; 21(11):847-52. PubMed ID: 23163650 [Abstract] [Full Text] [Related]
6. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies. Ruiz Salas V, Alegre M, Garcés JR, Puig L. Expert Rev Anticancer Ther; 2014 Jun 25; 14(6):741-9. PubMed ID: 24611655 [Abstract] [Full Text] [Related]
7. Sonic hedgehog pathway dysregulation in skin basal-cell carcinoma of a Polish population. Lesiak A, Sobolewska-Sztychny D, Danilewicz M, Rogowski-Tylman M, Sysa-Jedrzejowska A, Sobjanek M, Olejniczak-Staruch I, Narbutt J. Folia Histochem Cytobiol; 2013 Jun 25; 51(3):219-24. PubMed ID: 24203628 [Abstract] [Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE, Thompson LA, O'Bryant CL. Ann Pharmacother; 2014 Jan 25; 48(1):99-106. PubMed ID: 24259609 [Abstract] [Full Text] [Related]
9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C, Plaka M, Stratigos AJ. Future Oncol; 2014 May 25; 10(6):927-36. PubMed ID: 24941979 [Abstract] [Full Text] [Related]
10. Expression of sonic hedgehog signal transducers, patched and smoothened, in human basal cell carcinoma. Tojo M, Mori T, Kiyosawa H, Honma Y, Tanno Y, Kanazawa KY, Yokoya S, Kaneko F, Wanaka A. Pathol Int; 1999 Aug 25; 49(8):687-94. PubMed ID: 10504535 [Abstract] [Full Text] [Related]
11. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE. Future Oncol; 2015 Nov 25; 11(22):2997-3002. PubMed ID: 26437034 [Abstract] [Full Text] [Related]
15. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population. Lesiak A, Sobolewska-Sztychny D, Majak P, Sobjanek M, Wodz K, Sygut KP, Majsterek I, Wozniacka A, Narbutt J. Arch Dermatol Res; 2016 Jan 25; 308(1):39-47. PubMed ID: 26590974 [Abstract] [Full Text] [Related]
16. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, Gould SE, de Sauvage FJ. Nature; 2018 Oct 25; 562(7727):429-433. PubMed ID: 30297801 [Abstract] [Full Text] [Related]
17. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Danhof R, Lewis K, Brown M. Am J Clin Dermatol; 2018 Apr 25; 19(2):195-207. PubMed ID: 28887802 [Abstract] [Full Text] [Related]
19. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma. Leavitt E, Lask G, Martin S. Curr Treat Options Oncol; 2019 Nov 26; 20(11):84. PubMed ID: 31773379 [Abstract] [Full Text] [Related]